-$0.25 EPS Expected for Genenta Science S.p.A. (NASDAQ:GNTA) This Quarter

Brokerages expect Genenta Science S.p.A. (NASDAQ:GNTAGet Rating) to post earnings per share of ($0.25) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Genenta Science’s earnings. The firm is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Genenta Science will report full-year earnings of ($1.05) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.91) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Genenta Science.

GNTA has been the topic of a number of recent analyst reports. Maxim Group initiated coverage on Genenta Science in a research report on Thursday, January 13th. They set a “buy” rating and a $21.00 price target on the stock. Roth Capital reiterated a “buy” rating on shares of Genenta Science in a research report on Wednesday, January 12th.

Shares of GNTA stock opened at $5.70 on Tuesday. The company has a 50-day moving average price of $6.61. Genenta Science has a fifty-two week low of $5.11 and a fifty-two week high of $13.13.

About Genenta Science (Get Rating)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.

Further Reading

Get a free copy of the Zacks research report on Genenta Science (GNTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.